Progress in the development of a preventive HIV-1 vaccine.
Control of human immunodeficiency virus type-1 (HIV-1) infection is the foremost public health challenge at the turn of the millennium. Two decades, 22 million fatalities, and 40 million living victims after its discovery, HIV-1 continues its inexorable spread. Over the past few years, scientists have made tremendous progress in understanding the immunopathogenesis of HIV-1 infection and identifying potential targets for intervention with vaccines. Future progress will require a coordinated and proactive response to foster understanding of the benefits of vaccines and to encourage a receptive atmosphere for community vaccine testing and implementation.
Elizaga
Marnie L
ML
Seattle HIV-1 Vaccines Trial Unit, 901 Boren Ave, Suite 1320, Seattle, WA 98104, USA.
McElrath
M Juliana
MJ
D016915:AIDS Vaccines / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D022223:Vaccines, Subunit / Q000276:immunology
D016915:AIDS Vaccines; D022223:Vaccines, Subunit